Last reviewed · How we verify
NCT06231732
The Hi-tACS on Cognitive Function in Patients With Schizophrenia: a Pilot Study
NA trial testing high-frequency transcranial alternating current stimulation in Schizophrenia in 12 participants. Currently enrolling.
1 March 2024
Quick facts
| Lead sponsor | Sir Run Run Shaw Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 14 November 2023 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 August 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- high-frequency transcranial alternating current stimulation
- sham high-frequency transcranial alternating current stimulation
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
Sir Run Run Shaw Hospital
Who can join
18 and older, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a double-blind, randomized, controlled intervention study aimed at exploring whether high-frequency transcranial alternating current stimulation (Hi-tACS) can improve cognitive impairment in patients with schizophrenia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06231732
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of high-frequency transcranial alternating current stimulation
Trials testing the same drug.
- NCT06470516 — The Hi-tACS on Cognitive Function in Patients With Schizophrenia · NA · recruiting
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Sir Run Run Shaw Hospital trials
Trials by the same sponsor.
- NCT07453940 — Left Atrial Appendage Closure With Versus Without Pulsed Field Ablation in Atrial Fibrillation Patients With Mild Sympto · NA · recruiting
- NCT07508943 — Decision-making and Optimization of Ventilatory Support for AECOPD Patients · not yet recruiting
- NCT07514533 — The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma · Phase 2 · not yet recruiting
- NCT07350590 — Comparison Between Robotic and Laparoscopic Right Hemicolectomy · terminated
- NCT07457073 — AI-Powered Sound Analysis for COPD Screening · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06231732 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sir Run Run Shaw Hospital
- Last refreshed: 20 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06231732.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing